Cyclacel Pharmaceuticals, Inc. (CYCC)
NASDAQ: CYCC · Real-Time Price · USD
16.04
-1.11 (-6.47%)
At close: Jul 25, 2025, 4:00 PM
16.06
+0.02 (0.12%)
After-hours: Jul 25, 2025, 7:59 PM EDT
Company Description
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer medicines based on cell cycle, transcriptional regulation, epigenetics, and mitosis control biology in the United States.
Its lead product Plogosertib or plogo, a solid tumors and hematological malignancies, which is in Phase 1/2 clinical trial.
The company was founded in 1996 and is headquartered in Kuala Lumpur, Malaysia.
Cyclacel Pharmaceuticals, Inc.
| Country | Malaysia |
| Founded | 1992 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 12 |
| CEO | Sing Wong |
Contact Details
Address: Level 10, Tower 11 Kuala Lumpur, 592000 Malaysia | |
| Phone | 60 9 08517 7330 |
| Website | cyclacel.com |
Stock Details
| Ticker Symbol | CYCC |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001130166 |
| CUSIP Number | 23254L876 |
| ISIN Number | US23254L8019 |
| Employer ID | 91-1766850 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Sing Ee Wong | Chairman, Chief Executive Officer and President |
| Cu Seng Kiu | Executive Director, Chief Financial Officer and Secretary |
| Gill Christie | Director of Human Resources |
| Grace Kim | Investor Relations Executive |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 25, 2025 | 424B3 | Prospectus |
| Jul 24, 2025 | S-4 | Filing |
| Jul 24, 2025 | POS AM | Post-Effective amendments for registration statement |
| Jul 24, 2025 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Jul 24, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Jul 16, 2025 | 425 | Filing |
| Jul 16, 2025 | 8-K | Current Report |
| Jul 7, 2025 | DEF 14C | Filing |
| Jul 7, 2025 | 425 | Filing |
| Jul 7, 2025 | 8-K | Current Report |